Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. HYFT
HYFT logo

HYFT Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.140
Open
1.140
VWAP
1.08
Vol
433.73K
Mkt Cap
49.98M
Low
1.020
Amount
466.98K
EV/EBITDA(TTM)
--
Total Shares
46.71M
EV
42.23M
EV/OCF(TTM)
--
P/S(TTM)
2.39
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
Show More

Events Timeline

(ET)
2026-03-06
16:10:00
MindWalk Holdings Launches B Cell Llama Platform for Antibody Discovery
select
2026-01-11 (ET)
2026-01-11
14:50:00
MindWalk Advances Influenza Program Identifying Functional Constraints
select
2025-10-21 (ET)
2025-10-21
09:12:01
Kamil Isaev Steps Down as MindWalk Director Following Inability to Secure Majority Vote
select
2025-10-21
09:09:44
MindWalk Names R. Scott Areglado as CFO
select
2025-10-15 (ET)
2025-10-15
07:04:46
Thomas Lynch named chief business officer at MindWalk
select
2025-10-09 (ET)
2025-10-09
07:04:33
MindWalk Launches Stock Repurchase Program for Up to 2.3 Million Shares
select
2025-09-22 (ET)
2025-09-22
07:24:05
MindWalk Progresses AI-Developed GLP-1 Therapeutics Initiative
select

News

Yahoo Finance
9.5
03-12Yahoo Finance
MindWalk Reports 52% Revenue Growth in Q3
  • Significant Revenue Growth: MindWalk Holdings Corp reported a revenue of $4.2 million for Q3, marking a 52% year-over-year increase, indicating strong market performance, particularly with a strategic focus on the North American market.
  • Outstanding US Market Performance: The company's US revenue doubled year-over-year to $2.6 million, reflecting MindWalk's successful transition in the North American market, which is expected to further drive future revenue growth.
  • Increased R&D Investment: R&D expenses rose to $1.2 million in Q3 from $0.9 million last year, demonstrating the company's ongoing investment in advancing pipeline programs, although this poses pressure on short-term profitability.
  • Strong Cash Position: MindWalk ended Q3 with $14.2 million in cash, providing a solid financial foundation for future investments and growth, despite a net loss of $3.9 million, which is a significant improvement from last year's $22 million loss.
NASDAQ.COM
2.0
03-12NASDAQ.COM
MindWalk (HYFT) Q3 2026 Earnings Call Transcript
seekingalpha
9.5
03-12seekingalpha
MindWalk Q3 Earnings Beat Expectations with Revenue Growth
  • Earnings Performance: MindWalk Holdings Corp. reported a Q3 GAAP EPS of -$0.08, missing expectations by $0.04, indicating ongoing challenges in profitability despite revenue growth.
  • Revenue Surge: The company achieved Q3 revenue of $4.16M, reflecting a 52.4% year-over-year increase, surpassing market expectations by $0.82M, which highlights strong business momentum in a challenging economic environment.
  • Market Reaction: Although the EPS fell short of expectations, the significant revenue growth may bolster investor confidence in the company's future performance, potentially leading to a positive impact on its stock price.
  • Industry Comparison: Compared to peers like Avino Silver & Gold and Harmony Gold, MindWalk's revenue growth rate demonstrates its competitive position within the industry, although improvements in profitability are necessary to attract more investors.
Newsfilter
9.5
03-12Newsfilter
MindWalk Reports Third Consecutive Quarter of Revenue Growth
  • Significant Revenue Growth: MindWalk reported Q3 FY2026 revenue of CAD 4.2 million, a 52% increase year-over-year, demonstrating strong growth momentum in the biotech sector, particularly with a strategic focus on the North American market.
  • Outstanding US Market Performance: US revenue reached CAD 2.6 million, doubling from the previous year, reflecting MindWalk's successful expansion in biologics services, thereby enhancing its competitive position in the market.
  • First Platform Contract Signed: MindWalk signed a one-year LensAI platform contract with its largest enterprise AI client, marking the company's first recurring revenue agreement, which signifies a transformative shift in its revenue structure.
  • New Platform Launch: MindWalk launched the B cell Llama™ nanobody discovery platform aimed at addressing bottlenecks in multispecific antibody development, which is expected to drive future market opportunities exceeding $50 billion.
seekingalpha
9.5
03-11seekingalpha
MindWalk Scheduled to Announce Q3 Earnings on March 12
  • Earnings Announcement Date: MindWalk (HYFT) is set to announce its Q3 earnings on March 12 before market open, with investors keenly awaiting the performance to assess the company's future growth potential.
  • Expected EPS Improvement: The consensus EPS estimate stands at -$0.04, reflecting a significant year-over-year improvement of 93.9%, indicating that the company is making strides in narrowing its losses, which could positively influence investor sentiment.
  • Revenue Decline Forecast: The revenue estimate for MindWalk is projected at $3.34 million, representing a substantial year-over-year decline of 46.3%, highlighting the challenges the company faces in the current market environment, which may negatively impact its stock price.
  • Historical Performance Insights: Historical earnings data and analyst ratings for MindWalk will provide crucial insights for investors, aiding them in understanding the company's financial health and future growth potential.
Newsfilter
3.5
03-06Newsfilter
MindWalk Launches B Cell Llama™ Platform for VHH Nanobody Discovery
  • Platform Innovation: MindWalk has launched the B Cell Llama™ platform focused on the discovery of VHH nanobodies, with bispecific antibody sales projected to reach $50 billion by 2030, indicating significant commercial potential in the biopharmaceutical sector.
  • Research Validation: A study published in Biomacromolecules shows that VHH nanobodies in multivalent formats achieved potency 10 to 25 times greater than monovalent forms, demonstrating the effectiveness of modular design in overcoming resistance and potentially providing new avenues for therapy development.
  • Immune Memory Mechanism: The study found that VHH-nanoparticle complexes were preferentially internalized by immune cells associated with long-term immune memory, suggesting that certain VHH formats may not only neutralize targets but also aid the immune system in recognizing them in the future, which has significant clinical implications.
  • AI-Driven Drug Discovery: The LensAI™ platform guides the entire discovery process, ensuring that candidate functionality is prioritized over binding strength, thereby increasing the likelihood of successful drug development and further solidifying MindWalk's leadership position in the biopharmaceutical field.
Wall Street analysts forecast HYFT stock price to rise
1 Analyst Rating
Wall Street analysts forecast HYFT stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
5.00
Averages
5.00
High
5.00
Current: 0.000
sliders
Low
5.00
Averages
5.00
High
5.00
No data

No data

Valuation Metrics

The current forward P/E ratio for MindWalk Holdings Corp (HYFT.O) is -20.00, compared to its 5-year average forward P/E of -29.85. For a more detailed relative valuation and DCF analysis to assess MindWalk Holdings Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-29.85
Current PE
-20.00
Overvalued PE
-18.07
Undervalued PE
-41.63

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
5.58
Current PS
5.94
Overvalued PS
6.60
Undervalued PS
4.56

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

predict most bullish ticker this month
Intellectia · 114 candidates
Rsi Category: moderateMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Month Rise Prob: >= 65One Month Predict Return: >= 10.0%
Ticker
Name
Market Cap$
top bottom
SPKL logo
SPKL
Spark I Acquisition Corp
98.18M
APXT logo
APXT
Apex Treasury Corp
458.22M
AMST logo
AMST
Amesite Inc
8.37M
CZFS logo
CZFS
Citizens Financial Services Inc
278.29M
JNJ logo
JNJ
Johnson & Johnson
571.52B
CRBU logo
CRBU
Caribou Biosciences Inc
184.58M
best way to make 10 to 100
Intellectia · 45 candidates
Market Cap: 10.00M - 100.00MWeekly Average Turnover: >= 1,000,000Annual Revenue Yoy Growth: >= 0.0%
Ticker
Name
Market Cap$
top bottom
AMTX logo
AMTX
Aemetis Inc
98.64M
MIND logo
MIND
Mind Technology Inc
94.90M
HYFT logo
HYFT
MindWalk Holdings Corp
94.78M
SSTI logo
SSTI
SoundThinking Inc
93.71M
IROQ logo
IROQ
IF Bancorp Inc
91.20M
SYPR logo
SYPR
Sypris Solutions Inc
89.82M
give me 5 more that are bullish
Intellectia · 23 candidates
Price: <= $3.00Weekly Average Turnover: >= 1,000,000Rsi 14: <= 70Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Quarter Eps Qoq Growth: >= 10.0%Quarter Revenue Qoq Growth: >= 10.0%
Ticker
Name
Market Cap$
top bottom
SID logo
SID
Companhia Siderurgica Nacional SA
2.36B
PSEC logo
PSEC
Prospect Capital Corp
1.33B
IOVA logo
IOVA
Iovance Biotherapeutics Inc
996.39M
LDI logo
LDI
loanDepot Inc
893.07M
ECX logo
ECX
Ecarx Holdings Inc.
734.56M
BTBT logo
BTBT
Bit Digital Inc
721.79M

Whales Holding HYFT

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is MindWalk Holdings Corp (HYFT) stock price today?

The current price of HYFT is 1.07 USD — it has decreased -7.76

What is MindWalk Holdings Corp (HYFT)'s business?

MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.

What is the price predicton of HYFT Stock?

Wall Street analysts forecast HYFT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HYFT is5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is MindWalk Holdings Corp (HYFT)'s revenue for the last quarter?

MindWalk Holdings Corp revenue for the last quarter amounts to 4.16M USD, increased 52.42

What is MindWalk Holdings Corp (HYFT)'s earnings per share (EPS) for the last quarter?

MindWalk Holdings Corp. EPS for the last quarter amounts to -0.08 USD, decreased -87.88

How many employees does MindWalk Holdings Corp (HYFT). have?

MindWalk Holdings Corp (HYFT) has 0 emplpoyees as of March 30 2026.

What is MindWalk Holdings Corp (HYFT) market cap?

Today HYFT has the market capitalization of 49.98M USD.